Australian Gonococcal Surveillance Programme, 1 January to 31 March 2018
DOI:
https://doi.org/10.33321/cdi.2019.43.27Keywords:
antimicrobial resistance, disease surveillance, gonococcal infection, Neisseria gonorrhoeaeAbstract
The Australian National Neisseria Network (NNN) comprises reference laboratories in each state and territory that report data on antimicrobial susceptibility testing to an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). This report presents national gonococcal antimicrobial resistance surveillance data for the indicated quarter.
Downloads
References
Whiley DM, Jennison A, Pearson J, Lahra MM. Genetic characterisation of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin. Lancet Infect Dis. 2018;18(7):717–8.
European Centre for Disease Prevention and Control. Rapid Risk Assessment: Extensively drug-resistant (XDR) Neisseria gonorrhoeae in the United Kingdom and Australia. 2018. Available online: https://ecdc.europa.eu/en/publications-data/rapid-risk-assessment-extensively-drug-resistant-xdr-neisseria-gonorrhoeae-united
Lahra MM, Enriquez RP. Australian Gonococcal Surveillance Programme Annual Report, 2016. Commun Dis Intell (2018). 2018;42. pii: S2209-6051(18)00013-1.
Lahra MM, Ward A, Trembizki E, Hermanson J, Clements E, Lawrence A, et al. Treatment guidelines after an outbreak of azithromycin-resistant Neisseria gonorrhoeae in South Australia. Lancet Infect Dis. 2017;17(2):133–4.
Unemo M. Current and future antimicrobial treatment of gonorrhoea—the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis. 2015;15:364.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2019 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
